Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS

Table 1

Main pharmacokinetics of celecoxib in three groups (n = 5).

Parameters	A	B	C
Cmax (μg/l)	1380.55 ± 765.91	3240.00 ± 610.52	3756.71 ± 264.99
t1/2 (h)	4.34 ± 2.62	3.77 ± 0.76	2.93 ± 0.75
Tmax (h)	2.60 ± 0.89	3.40 ± 0.89	3.40 ± 0.89
CLz/F (l/kg·h)	3.49 ± 1.37	2.03 ± 0.52	1.64 ± 0.20
AUC(0–t) (μg/l·h)	10,821.66 ± 5555.93	25,675.06 ± 7187.40	30,576.35 ± 3593.70
AUC(0–∞) (μg/l·h)	11,455.84 ± 6449.11	26,103.55 ± 7186.70	30,835.89 ± 3714.18
MRT(0–t) (h)	6.70 ± 0.52	6.92 ± 0.60	6.46 ± 0.32
MRT(0–∞) (h)	7.77 ± 1.70	7.32 ± 0.68	6.64 ± 0.42

Compared to group A (ANOVA), ; ; .